"We are pleased to receive CE Mark approval and TGA listing for the new i-FACTOR Flex FR biologic bone graft," said Glen Kashuba, CEO at Cerapedics.

"Silk has been used in medical applications for many years, and by adding purified silk fibers to the proven efficacy and safety of our P-15 bone graft technology we are now able to pursue exciting new applications for this platform."

The i-FACTOR Flex FR biologic bone graft is based on original P-15 technology developed by Cerapedics to support bone growth through cell attachment and osteoblast differentiation.

The new product includes silk from larva of the bombyx mori moth that is purified to remove the protein sericin, resulting in biocompatible fibroin fibers that enhance cohesion and mechanical properties.

Cerapedics has conducted a limited market release for i-FACTOR Flex FR biologic bone graft in order to obtain feedback from surgeons on a range of product enhancements.

To date more than 60 procedures have been successfully completed using i-FACTOR Flex FR biologic bone graft, primarily in spinal fusion applications.

"Based on our clinical experience thus far, the new i-FACTOR Flex FR biologic bone graft appears to offer significant advantages in handling while maintaining the safety and efficacy of the first generation i-FACTOR with P-15 technology," said Dr. Niall Craig, consultant orthopedic surgeon at NHS Grampian in the United Kingdom.

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary synthetic small peptide (P-15) technology platform.

i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process.